Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.34 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | CCR5 | P51681 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14161971 | 0.85 | PTGDR2 (0.52) | PTGDR2HPGDTSHRERN1POLB | |
| SCHEMBL1415050 | 0.82 | PTGDR2 (0.44) | PTGDR2HPGDTSHRERN1TDP1 | |
| SCHEMBL128987 | 0.76 | PTGDR2 (0.60) | PTGDR2HPGDTSHRERN1POLB | |
| SCHEMBL17693643 | 0.75 | FDPS (0.38) | HPGDTSHRPOLBTDP1L3MBTL1 | |
| SCHEMBL1411706 | 0.74 | GAA (0.36) | PTGDR2LMNAALDH1A1CCR5CYP1A2 | |
| SCHEMBL17695780 | 0.73 | FDPS (0.46) | HPGDPOLBTDP1L3MBTL1NPC1 | |
| SCHEMBL17695782 | 0.73 | FDPS (0.46) | HPGDPOLBTDP1L3MBTL1NPC1 | |
| SCHEMBL29888853 | 0.73 | PTGDR2 (0.60) | PTGDR2HPGDTSHRERN1POLB | |
| SCHEMBL4960450 | 0.73 | PTGDR2 (0.60) | PTGDR2HPGDTSHRERN1POLB | |
| SCHEMBL17693638 | 0.73 | FDPS (0.38) | HPGDTSHRPOLBTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100112061-A1 | Monophosphates as Mutual Prodrugs of Muscarinic Receptor Antagonists and Beta-Agonists for the Treatment of COPD And Chronic Bronchitis | GILEAD SCIENCES, INC. | 2010-05-06 | — | — | US | disclosed |
| US-20100098641-A1 | Monophosphates as Mutual Prodrugs of Anti-Inflammatory Signal Transduction Modulators (AISTM's) and Beta-Agonists for the Treatment of Pulmonary Inflammation and Bronchoconstriction | GILEAD SCIENCES, INC. | 2010-04-22 | — | — | US | disclosed |
| US-20090318396-A1 | CORTICOSTEROID LINKED BETA-AGONIST COMPOUNDS FOR USE IN THERAPY | GILEAD SCIENCES, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| EP-2125841-A1 | MONOPHOSPHATES AS MUTUAL PRODRUGS OF ANTI-INFLAMMATORY SIGNAL TRANSDUCTION MODULATORS (AISTM'S) AND BETA-AGONISTS FOR THE TREATMENT OF PULMONARY INFLAMMATION AND BRONCHOCONSTRICTION | Gilead Sciences, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| EP-2114972-A2 | MONOPHOSPHATES AS MUTUAL PRODRUGS OF MUSCARINIC RECEPTOR ANTAGONISTS AND BETA-AGONISTS FOR THE TREATMENT OF COPD AND CHRONIC BRONCHITIS | Gilead Sciences, Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008076265-A1 | MONOPHOSPHATES AS MUTUAL PRODRUGS OF ANTI-INFLAMMATORY SIGNAL TRANSDUCTION MODULATORS (AISTM'S) AND β-AGONISTS FOR THE TREATMENT OF PULMONARY INFLAMMATION AND BRONCHOCONSTRICTION | GILEAD SCIENCES, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008076269-A2 | MONOPHOSPHATES AS MUTUAL PRODRUGS OF MUSCARINIC RECEPTOR ANTAGONISTS AND β-AGONISTS FOR THE TREATMENT OF COPD AND CHRONIC BRONCHITIS | GILEAD SCIENCES, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318396-A1 | CORTICOSTEROID LINKED BETA-AGONIST COMPOUNDS FOR USE IN THERAPY | ADRB1, ADRB2, ADRB3 | PTGDR2 173/4885HPGD 1405/4885TSHR 466/4885 |
| US-20100098641-A1 | Monophosphates as Mutual Prodrugs of Anti-Inflammatory Signal Transduction Modulators (AISTM's) and Beta-Agonists for the Treatment of Pulmonary Inflammation and Bronchoconstriction | ADRB1, ADRB2, PDE11A | PTGDR2 441/4885HPGD 1299/4885TSHR 1563/4885 |
| US-20100112061-A1 | Monophosphates as Mutual Prodrugs of Muscarinic Receptor Antagonists and Beta-Agonists for the Treatment of COPD And Chronic Bronchitis | ADRB1, ADRB2, CHRM3 | PTGDR2 189/4885HPGD 301/4885TSHR 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.